Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half ...

CDI Labs Inc., a leading provider of services for proteome-wide antibody profiling and target identification, today announced the launch of its Pan-isotype Analysis Platform for serum antibody ...